Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

@article{Bourlire2017SofosbuvirVA,
  title={Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.},
  author={Marc Bourli{\`e}re and Stuart Gordon and Steven L. Flamm and Curtis L. Cooper and Alnoor S Ramji and M J Tong and Natarajan Ravendhran and John Moore Vierling and Tram Anh T. Tran and Stephen Pianko and Meena B. Bansal and Victor de Ledinghen and Robert Hyland and Luisa M. Stamm and Hadas Dvory-Sobol and Evguenia S. Svarovskaia and J Zhang and Kuo Chin Huang and Gopinath M Subramanian and Diana M. Brainard and John McHutchison and Elizabeth C. Verna and Peter Buggisch and Charles S. Landis and Ziad Younes and M P Curry and Simone Irene Strasser and Eugene R Schiff and K Rajender Reddy and Michael P. Manns and Kris V. Kowdley and Stefan Zeuzem},
  journal={The New England journal of medicine},
  year={2017},
  volume={376 22},
  pages={2134-2146}
}
BACKGROUND Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options. METHODS We conducted two phase 3 trials involving patients who had been previously treated with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1 infection who had previously received a regimen containing an NS5A inhibitor were randomly… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 114 times over the past 90 days. VIEW TWEETS
42 Citations
18 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Similar Papers

Loading similar papers…